drugset / Trial / NCT00038428
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
Timeline
- Start
- 2001-06
- Primary completion
- 2005-07
- Completion
- 2005-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | canfosfamide | Small molecule | — | Intravenous |